Anti-angiogenic therapies are a novel treatment modality for many adult and pediatric cancers and use of anti-angiogenic agents in the adult clinical world has already begun. In prior work done at Columbia University, Dr Soffer and his colleagues have shown that antibody to Vascular Endothelial Growth Factor (VEGF), the most important of a large cadre of angiogenic factors, blocks tumor growth in both Wilms tumor and neuroblastoma. This anti-VEGF agent, Bevacizumab, is in current clinical use in the treatment of metastatic colon cancer.